Angelo Lombardi
Angelo Lombardi, PhD
Assistant Professor, Università Vita-Salute San Raffaele
Prof. Lombardo obtained his PhD in Cellular and Molecular Biology in 2011, conducting research in Luigi Naldini's lab on innovative gene therapy approaches utilizing artificial nucleases and targeted genome editing. His early studies were groundbreaking, representing the first reports of gene editing in clinically relevant cell types, including human embryonic stem cells and hematopoietic progenitors. His significant contributions to the field include identifying the human AAVS1 locus as a genomic safe harbor for transgenesis and developing pioneering strategies to assess the specificity of artificial nucleases.
As a Project Leader, he demonstrated targeted gene correction in human hematopoietic stem cells. Since 2013, Angelo has served as an Assistant Professor at Università Vita-Salute San Raffaele, and since 2015, he has been a Group Leader at the SR-Tiget. His team has developed a novel gene therapy modality that leverages targeted epigenetic editing to permanently silence gene expression.
Angelo has published over 40 articles in peer-reviewed journals, including first or last author papers in prestigious journals such as Cell, Nature, Nature Biotechnology, and Nature Methods. He is listed as an inventor on several patent applications stemming from these publications. Additionally, he has received numerous prizes, including the Young Investigator Award from the European Society of Gene and Cell Therapy (ESGCT) and the Excellence in Research Award from the American Society of Gene and Cell Therapy (ASGCT). He has been a recurring plenary speaker at major international conferences, including the Keystone Symposia, ASGCT, ESGCT, and ISSCR.